Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new survey reveals that U.S. military veterans and active-duty service members with non-muscle-invasive bladder cancer (NMIBC) are struggling to access timely, recommended care. Nearly half reported difficulty obtaining provider-recommended treatments, and 59% cited treatment availability — including BCG shortages — as the biggest barrier. Many were also diagnosed younger than expected, with over half receiving a diagnosis by age 50.
A Harris Poll survey commissioned by ImmunityBio sheds light on the significant care access challenges facing U.S. military veterans and active-duty service members diagnosed with non-muscle-invasive bladder cancer (NMIBC). Of the 100 participants surveyed, 49% reported difficulty accessing their provider's recommended treatment, 44% experienced long waits between diagnosis and treatment, and 27% struggled to coordinate care between VA and non-VA providers.
Perhaps most striking is the age of diagnosis — 53% were diagnosed by age 50, and 28% by age 40, suggesting earlier-than-typical onset potentially linked to military service exposures. Over half of respondents reported exposure to contaminated water, and 31% to burn pits.
By the Numbers:
Why it matters: This survey highlights systemic gaps in cancer care for those who served — from supply shortages to coordination failures — underscoring the urgent need for veteran-tailored resources and expanded treatment access within the VA system.